A clinical study of tremelimumab alone or in combination with olaparib in patients with advanced epithelial ovarian cancer.

Stephanie Gaillard,Maureen Berg,Jeanne Harrison,Peng Huang,James M. Leatherman,Michele Doucet,Rupashree Sen,Aditya Suru,Hongyan Cai,Jennifer N. Durham,Danijela Jelovac,Ashley Cimino-Mathews,Sudipto Ganguly,Leisha A. Emens

A clinical study of tremelimumab alone or in combination with olaparib in patients with advanced epithelial ovarian cancer.

2020

Stephanie Gaillard
Maureen Berg
Jeanne Harrison
Peng Huang
James M. Leatherman
Michele Doucet
Rupashree Sen
Aditya Suru
Hongyan Cai
Jennifer N. Durham
Danijela Jelovac
Ashley Cimino-Mathews
Sudipto Ganguly
Leisha A. Emens

6045Background: Single agent immunotherapy (IO) has shown only modest clinical activity for the treatment of ovarian cancer. The combination of anti-programmed death-1 and PARP inhibitors showed pr...

Keywords:

Oncology
Internal medicine
Tremelimumab
Olaparib
Medicine
epithelial ovarian cancer
clinical study
in patient
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations